Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review
International Journal of Molecular Sciences · 12.06.2025 · 26 (12) · 5634
DOI: 10.3390/ijms26125634 ↗Kurz gefasst
Scoping Review in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.06.2025. Verfasst von Marco Meleiro und 1 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Master's in Medicine, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-313 P…. Hauptthemen laut MEDLINE: Brain Neoplasms, Epigenesis, Genetic, Glioblastoma. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 287 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centro de Investigação do IPO Porto, Research Center of IPO Porto.
Abstract (Originalsprache)
Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor with a dismal prognosis despite advances in multimodal treatment. Conventional therapies fail to achieve durable responses due to GBM’s molecular heterogeneity and capacity to evade therapeutic pressures. Epigenetic alterations have emerged as critical contributors to GBM pathobiology, including aberrant DNA methylation, histone modifications, and non-coding RNA (ncRNA) dysregulation. These mechanisms drive oncogenesis, therapy resistance, and immune evasion. This scoping review evaluates the current state of knowledge on epigenetic modifications in GBM, synthesizing findings from original articles and preclinical and clinical trials published over the last decade. Particular attention is given to MGMT promoter hypermethylation status as a biomarker for temozolomide (TMZ) sensitivity, histone deacetylation and methylation as modulators of chromatin structure, and microRNAs as regulators of pathways such as apoptosis and angiogenesis. Therapeutically, epigenetic drugs, like DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis), appear as promising approaches in preclinical models and early trials. Emerging RNA-based therapies targeting dysregulated ncRNAs represent a novel approach to reprogram the tumor epigenome. Combination therapies, pairing epigenetic agents with immune checkpoint inhibitors or chemotherapy, are explored for their potential to enhance treatment response. Despite these advancements, challenges such as tumor heterogeneity, the blood–brain barrier (BBB), and off-target effects remain significant. Future directions emphasize integrative omics approaches to identify patient-specific targets and refine therapies. This article thus highlights the potential of epigenetics in reshaping GBM treatment paradigms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Integrated Master's in Medicine, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
- Department of Pathology and Molecular Immunology, School of Medicine & Biomedical Sciences, University of Porto (ICBAS-UP), Rua Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
- Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal.
- Cancer Biology & Epigenetics Group-Research Center of IPO Porto (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Centre Raquel Seruca (Porto.CCC), Rua Dr. António Bernardino de Al…
ORCID-Profile: Marco Meleiro, Rui Henrique
Förderung
- Centro de Investigação do IPO Porto
- Research Center of IPO Porto
Zitieren
APA
Meleiro, M., & Henrique, R. (2025). Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review. International Journal of Molecular Sciences, 26(12), 5634. https://doi.org/10.3390/ijms26125634
Vancouver
Meleiro M, Henrique R. Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review. International Journal of Molecular Sciences. 2025;26(12):5634. doi:10.3390/ijms26125634
BibTeX
@article{Meleiro2025,
author = {Meleiro, Marco and Henrique, Rui},
title = {Epigenetic Alterations in Glioblastoma Multiforme as Novel Therapeutic Targets: A Scoping Review},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {12},
pages = {5634},
doi = {10.3390/ijms26125634}
}
EUVIMED